Search

Your search keyword '"Gertz, Morie A"' showing total 5,541 results

Search Constraints

Start Over You searched for: Author "Gertz, Morie A" Remove constraint Author: "Gertz, Morie A"
5,541 results on '"Gertz, Morie A"'

Search Results

1. Capillary leak phenotype as a major cause of death in patients with POEMS syndrome: MULTIPLE MYELOMA, GAMMOPATHIES

2. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events

3. Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform

4. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms

5. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma

6. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

8. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

9. Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion

13. Retreatment of multiple myeloma with previously refractory drugs

14. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies

17. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

18. Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis

20. Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

23. Muscle and fat composition in patients with newly diagnosed multiple myeloma

24. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

25. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma

26. Utility of flow cytometry screening before MRD testing in multiple myeloma

27. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma

29. Amyloidosis

31. Prognostic impact of patient-reported symptoms in multiple myeloma

32. Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

33. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

34. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

36. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

38. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.

39. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen

40. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

42. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy

43. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update

44. Outcomes after biochemical or clinical progression in patients with multiple myeloma

45. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis

48. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

49. Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis.

50. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma

Catalog

Books, media, physical & digital resources